Back to Search
Start Over
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
- Source :
- Nature Reviews Cancer; Jun2009, Vol. 9 Issue 6, p445-452, 8p, 2 Diagrams, 3 Charts
- Publication Year :
- 2009
-
Abstract
- Indoleamine-2,3-dioxygenase (IDO) is an immunosuppressive enzyme capable of inhibiting a destructive maternal T cell response against allogeneic fetuses. Expression of IDO is evident in tumours and is thought to enable escape from immunologically mediated rejection. Consequently, clinical trials using an inhibitor of IDO, 1-methyltryptophan (1MT), have been initiated. However, a review of the current literature indicates that we are far from understanding the biological relevance of IDO expression during tumorigenesis. A better understanding of IDO biology is needed to comprehend the effect of IDO inhibitors and to provide a rationale for their therapeutic application in cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- CANCER treatment
IMMUNOSUPPRESSIVE agents
CARCINOGENESIS
TRYPTOPHAN
T cells
Subjects
Details
- Language :
- English
- ISSN :
- 1474175X
- Volume :
- 9
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Nature Reviews Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 40084289
- Full Text :
- https://doi.org/10.1038/nrc2639